KALIVIR has developed a potent, novel oncolytic platform called the Vaccinia Enhanced Template (VET™). KaliVir’s VET™ Platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and expression of therapeutic transgene in the tumor. VET™ Platform mechanisms can include immune modulations to specifically enhance the anti-tumoral immunity.
VET™ platform is designed to:
- Enhance systemic (IV) delivery capabilities
- Enhance tumor-targeted replication
- Enhance viral spread to metastatic tumors
- Enhance viral spread within tumor microenvironment.